Three Overlooked, Undervalued Picks for Today's Energy Market
Source: Chen Lin   (5/12/16)
The energy sector is a tricky place to invest right now, with a fine line separating the next bankruptcy candidate from a tenbagger. Chen Lin of the popular newsletter What Is Chen Buying?, What Is Chen Selling? helps investors navigate this minefield with three companies he believes will come out on top. More >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Source: George S. Mack of The Life Sciences Report  (5/11/16)
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. More >

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Source: Special to The Life Sciences Report  (5/11/16)
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. More >

Stan Druckenmiller: The Bull Market Is Exhausted; Make the Move to Gold
Source: The Gold Report  (5/10/16)
Legendary investor Stan Druckenmiller, founder of Duquesne Capital Management LLC, told the Sohn Investment Conference in New York last week that he is bullish on gold and bearish on the stock market. Gold, he told the conference, "is our largest currency allocation." More >

When Will Uranium Emerge from the Shadow of Fukushima?
Source: The Energy Report  (5/9/16)
Joe Reagor of ROTH Capital Partners explains the factors that have kept uranium spot prices down, how much longer they will be in effect, and why uranium should be on investors' radar screens today. He also discusses four uranium companies that are in position to benefit from the looming uranium shortage. More >

After COT Data Shocker, No Surprise Gold Is Down
Source: Jack Chan for The Gold Report  (5/9/16)
Technical analyst Jack Chan shows why Friday's COT data was so shocking and what it means for gold. More >

Energy Sector Showing Sell Signals
Source: Jack Chan for The Energy Report  (5/9/16)
Technical analyst Jack Chan highlights sell signals in the energy sector. More >

Commercial Gold 'Hedgers' Turn Up the Heat
Source: Michael Ballanger  (5/7/16)
Michael Ballanger discusses the most recent COT report, which shows levels not seen since 2010–2011. More >

Gold and Silver Companies with the Potential to Move the Needle
Source: Patrice Fusillo of The Gold Report  (5/5/16)
The two times mining companies add the most value are upon first discovery and when they are nearing development and production. Joe Reagor of ROTH Capital Partners focuses on the latter group, and in this interview with The Gold Report, he discusses a handful of gold and silver companies poised to move up the value curve even if gold and silver don't go up. More >

Give me Facts or at Least Logical Opinions
Source: Bob Moriarty  (5/5/16)
Bob Moriarty of 321Gold busts the myth of a Comex bank and examines the role of small speculators in commodities markets. More >

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Source: Special to The Life Sciences Report  (5/4/16)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSomeâ„¢ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. More >

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline
Source: Jason Napodano  (5/4/16)
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders. Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential. More >

Some of Brien Lundin's Precious Metals Picks Are Up More Than 400%. What Is Next?
Source: Patrice Fusillo of The Gold Report  (5/3/16)
A battle royale is brewing between gold bulls and commercial traders who are short gold, says Brien Lundin, publisher of Gold Newsletter. That tug of war, which should play out in the coming weeks, could result in either a severe correction or a spectacular rise in the price of gold and silver. No matter which way it goes, in this interview with The Gold Report, Lundin recommends that investors continue to look at companies with world-class resources that are still being priced at a fraction of what their values should be. Lundin should know; some of his recommendations are up more than 400% from December and January. More >

If A=B and B=C, Does A=C?
Source: Bob Moriarty  (5/3/16)
No need to listen to the "experts" to understand the ins and outs of commodities markets, according to Bob Moriarty of 321Gold. If investors use common sense and basic tools available online, they too can be successful. More >

Gold and Silver Challenging Major Resistance
Source: Jack Chan for The Gold Report  (4/30/16)
Both gold and silver are challenging major resistance while the U.S. dollar is testing support, says technical analyst Jack Chan. A break will help clarify the technical prospect going forward. More >

We Cannot Predict But We Can Prepare
Source: Jack Chan for The Energy Report  (4/30/16)
Technical analyst Jack Chan says the charts suggest that the major correction in the oil service sector since 2014 is now complete. More >

Fratboys at the Punchbowl
Source: Joe McAlinden   (4/29/16)
The Federal Reserve, like chaperones at a fraternity house party, has appeared overly concerned about the prospect of upsetting the party-goers and has backed off from earlier indications that it would raise rates four times this year, says Joe McAlinden of McAlinden Research Partners. More >

Precious Metals Every Bit as Explosive as Secretariat at the Belmont Stakes
Source: Michael Ballanger  (4/29/16)
The charts tell the story, says precious metals expert Michael Ballanger, adding that the mining and metals market have the forward momentum of Secretariat as he clinched the Triple Crown. More >

The Two Best Calls Ever on a Gold Bottom
Source: Bob Moriarty  (4/28/16)
Bob Moriarty of 321Gold calls out the work of two men who got it right on gold and silver. More >

Let Volatility Power Your Micro-Cap Biotechs
Source: George Mack of The Life Sciences Report  (4/27/16)
ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report, Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on. More >

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
Source: Special to The Life Sciences Report  (4/27/16)
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. More >

What Steve Jobs Knew About the Internet Can Make You a Better Gold Investor
Source: Bob Moriarty  (4/27/16)
Of all the people in the tech world, Steve Jobs perhaps understood the potential of the Internet better than any of his peers. Bob Moriarty of 321Gold discusses how Jobs' insight can provide lessons on gold manipulation and what moves markets. More >

The Significance of Rising Commodities Prices…
Source: Michael Ballanger  (4/27/16)
Precious metals expert Michael Ballanger expounds on how Federal Reserve policy affects the commodities markets, and expresses cautious optimism about how that policy will play out in gold markets. More >

Back-to-Back Good News for Nevada Energy Metals
Source: Keith Kohl   (4/27/16)
Not long after Nevada Energy Metals expanded its presence in the Clayton Valley, the company announced it added claims to its San Emidio property. Keith Kohl of Oil & Gas Trader explains what this means to investors. More >

Mining M&A Warming Up with Reservoir and Sunridge Deals
Source: Adrian Day  (4/27/16)
Adrian Day shares additional thoughts on Nevsun's deal to buy Reservoir Minerals. The investment conclusion—to hold—remains. And he has an update on Sunridge being acquired. More >